U.S. markets open in 6 hours 24 minutes
  • S&P Futures

    4,229.00
    +19.00 (+0.45%)
     
  • Dow Futures

    33,402.00
    +142.00 (+0.43%)
     
  • Nasdaq Futures

    13,472.50
    +80.50 (+0.60%)
     
  • Russell 2000 Futures

    1,978.80
    +9.30 (+0.47%)
     
  • Crude Oil

    91.88
    -0.05 (-0.05%)
     
  • Gold

    1,802.10
    -11.60 (-0.64%)
     
  • Silver

    20.51
    -0.23 (-1.09%)
     
  • EUR/USD

    1.0316
    +0.0014 (+0.13%)
     
  • 10-Yr Bond

    2.7860
    0.0000 (0.00%)
     
  • Vix

    19.74
    -2.03 (-9.32%)
     
  • GBP/USD

    1.2227
    +0.0009 (+0.07%)
     
  • USD/JPY

    132.7140
    -0.1590 (-0.12%)
     
  • BTC-USD

    24,555.61
    +1,597.74 (+6.96%)
     
  • CMC Crypto 200

    577.96
    +46.73 (+8.80%)
     
  • FTSE 100

    7,507.11
    0.00 (0.00%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories"

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ: RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ: DYN) with a Buy rating and a price target of $17.

  • "We believe that Avidity and Dyne are an intriguing small-cap story that, while not immune to the selloff of the biotech sector over the past seven months, warrants a fresh look by investors, Chardan analysts wrote.

  • Chardan says Avidity's antibody oligonucleotide conjugate (AOC) design and Dyne's proprietary FORCE design platform leverage well-characterized components.

  • Related: Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew.

  • "The value created by the companies thus far is the well-characterized understanding of how to get all of the components to work together in an optimum fashion," Chardan added.

  • Hence, the key reason Chardan believes that Avidity's AOC and Dyne's FORCE design approach is an enabling technology that can advance small RNA therapeutics to move beyond the liver successfully.

  • Price Action: DYN stock is down 0.93% at $10.35, and RNA shares are up 5.63% at $18.76 during the market session on the last check Wednesday.

Latest Ratings for DYN

Date

Firm

Action

From

To

Oct 2020

JP Morgan

Initiates Coverage On

Overweight

Oct 2020

Stifel

Initiates Coverage On

Buy

Oct 2020

Jefferies

Initiates Coverage On

Buy

View More Analyst Ratings for DYN

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.